C4 Therapeutics Appoints New Chief Medical Officer
Ticker: CCCC · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1662579
| Field | Detail |
|---|---|
| Company | C4 Therapeutics, Inc. (CCCC) |
| Form Type | 8-K |
| Filed Date | Mar 8, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $22.00, $19.00, $11 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
C4 Therapeutics names new CMO, Dr. Adam Schomer, effective March 7th.
AI Summary
C4 Therapeutics, Inc. announced on March 8, 2024, that Dr. Adam R. Schomer has been appointed as Chief Medical Officer, effective March 7, 2024. Dr. Schomer previously served as Senior Vice President, Clinical Development at the company. The filing also notes the departure of Dr. Steven R. Deitcher as Chief Medical Officer.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's strategic direction and clinical trial execution.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate shifts in strategy or challenges that may affect the company's future performance.
Key Players & Entities
- C4 Therapeutics, Inc. (company) — Registrant
- Dr. Adam R. Schomer (person) — Appointed Chief Medical Officer
- March 7, 2024 (date) — Effective date of appointment
- Dr. Steven R. Deitcher (person) — Departing Chief Medical Officer
- March 8, 2024 (date) — Date of report
FAQ
Who has been appointed as the new Chief Medical Officer of C4 Therapeutics, Inc.?
Dr. Adam R. Schomer has been appointed as the new Chief Medical Officer of C4 Therapeutics, Inc.
When was the appointment of the new Chief Medical Officer effective?
The appointment of Dr. Adam R. Schomer was effective March 7, 2024.
What was Dr. Adam R. Schomer's previous role at C4 Therapeutics, Inc.?
Dr. Adam R. Schomer previously served as Senior Vice President, Clinical Development at C4 Therapeutics, Inc.
Who has departed from the role of Chief Medical Officer?
Dr. Steven R. Deitcher has departed from the role of Chief Medical Officer.
What is the filing date of this 8-K report?
This 8-K report was filed on March 8, 2024.
Filing Stats: 935 words · 4 min read · ~3 pages · Grade level 13.5 · Accepted 2024-03-08 16:10:39
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo
- $22.00 — n exercise price per share greater than $22.00 (the " Eligible Options "). The reprice
- $19.00 — exercise price for repriced options is $19.00 per share, which was selected as it was
- $11 — exercise price for repriced options is $11.88, the 52-week high trading price for
Filing Documents
- cccc-20240308.htm (8-K) — 32KB
- 0001628280-24-009967.txt ( ) — 157KB
- cccc-20240308.xsd (EX-101.SCH) — 2KB
- cccc-20240308_lab.xml (EX-101.LAB) — 22KB
- cccc-20240308_pre.xml (EX-101.PRE) — 13KB
- cccc-20240308_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: March 8, 2024 By: /s/ Jolie M. Siegel Jolie M. Siegel Chief Legal Officer